Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.86 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | PHGDH | O43175 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456205 | 0.92 | HPGD (1.00) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL1450838 | 0.91 | HRH3 (0.78) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL13636330 | 0.90 | HRH3 (1.00) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL522513 | 0.90 | HPGD (0.75) | HPGDHRH3GAASMN1; SMN2PHGDH | |
| SCHEMBL13211156 | 0.89 | HPGD (0.73) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL10184001 | 0.89 | HRH3 (0.78) | HPGDHRH3GAASMN1; SMN2USP2 | |
| Hydrochloric Acid SCHEMBL1177194 | 0.89 | HRH3 (0.97) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL521532 | 0.86 | HRH3 (1.00) | HPGDHRH3 | |
| Bavisant SCHEMBL522603 | 0.86 | HRH3 (1.00) | HPGDHRH3GAASMN1; SMN2USP2 | |
| SCHEMBL3405905 | 0.85 | PHGDH (0.68) | HPGDHRH3SMN1; SMN2PHGDHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272835-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | CCL11, CCR1, CCR10 | HPGD 2061/4885HRH3 76/4885GAA 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.